The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose control but also improve cardiovascular, gastric, hepatic, and renal values. Throughout 2024, research has also indicated GLP-1 drugs may reduce risks for obesity-related cancer as well…
